We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The comp... Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003. Show more
HOUSTON, April 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi...
HOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi...
HOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to...
HOUSTON, April 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
HOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.5799 | -37.1741176471 | 4.25 | 4.5699 | 2.35 | 727786 | 3.67251668 | CS |
4 | -1.4299 | -34.8756097561 | 4.1 | 7.6699 | 2.35 | 4617371 | 4.16840957 | CS |
12 | -5.8879 | -68.7999532601 | 8.558 | 9.9875 | 2.35 | 1575701 | 4.30089728 | CS |
26 | -10.0799 | -79.0580392157 | 12.75 | 14.42398 | 2.35 | 800631 | 4.87539026 | CS |
52 | -23.9299 | -89.9620300752 | 26.6 | 44.8 | 2.35 | 1144354 | 10.65253889 | CS |
156 | -120.3299 | -97.8291869919 | 123 | 172.398 | 2.35 | 526119 | 40.11634974 | CS |
260 | -364.1299 | -99.2720556161 | 366.8 | 486.8 | 2.35 | 527866 | 93.14446644 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions